# A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

> **NCT04380961** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 212 (actual)

## Conditions studied

- Critical Confirmed Coronavirus Disease (COVID)-19

## Interventions

- **DRUG:** Sirukumab
- **DRUG:** Placebo
- **OTHER:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT04380961
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-24
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-06-24
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04380961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04380961, "A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT04380961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*